Recent studies suggest that PXR may be a useful target for pharmacological therapies in various conditions, including liver disease [165], and inflammatory bowel diseases (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC) [164,166]. This evidence concerns the gene NR1I2 and inflammatory bowel disease.